The use of roxithromycin in the treatment of acute bacterial rhinosinusitis
https://doi.org/10.21518/2079-701X-2018-21-61-65
Abstract
According to epidemiological studies, bacterial rhinosinusitis is one of the most common pathologies of ENT-organs on an upward trend. Rhinosinusitis significantly reduces the patient’s quality of life and, in the absence of timely treatment, can lead to serious complications. Macrolide antibiotics are effective drugs in the treatment of rhinosinusitis. Roxithromycin (Esparoxy), one of modern macrolides, showed good results. The article provides characteristics of this drug, reflects the high quality of efficacy and safety in the treatment of bacterial rhinosinusitis, with due regard to the experience of the Russian and foreign authors.
About the Authors
A. A. Krivopalov
Federal State Budgetary Institution of Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Krivopalov Alexander Alexandrovich – Dr. of Sci. (Med.), Senior Researcher
9 Bronnitskaya, St. Petersburg, 190013
A. Р. Smirnov
Federal State Budgetary Institution of Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Smirnov Artem Pavlovich – Clinical Intern
9 Bronnitskaya, St. Petersburg, 190013
References
1. Krivopalov A.A. Definitions, classifications, etiology and epidemiology of rhinosinusitis (literature review). Ros. Rinologia. 2016; 24 (2): 39-45. (In Russ).
2. Ryazantsev S.V. Principles of etiopathogenetic therapy of acute sinusitis: Methodological guidelines. 2013. (In Russ).
3. Fokkens W. J. et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.
4. Krivopalov A.A., Yanov Yu.K., Korneenkov A.A., Scherbuk, A.Yu., Artyushkin S.A., Vakhrushev S.G. Epidemiological and demographic features of intracranial oto-and rhinosinusogenic purulent-inflammatory complications in the Russian Federation. Vestn. Khirurgii Im. I.I. Grekova. 2016; 175 (2): 36-42. (In Russ).
5. Denisov I.N. Acute rhinosinusitis: clinical guidelines. 2014. (In Russ).
6. Chow A.W. et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clinical Infectious Diseases. 2012;54(8):e72-e112.
7. Strachunsky L.S., Belousov Yu.B., Kozlov S.N. A practical guide to anti-infective chemotherapy. Smolensk. 2007. (In Russ).
8. Kolenchukova O.A. Characteristics of the nasal mucosa microbiocenosis in acute bacterial rhinosinusitis. Vestn. Otorinolar. 2017; 82 (5): 28-31. (In Russ).
9. Felmigham D., Reinert R.R., Hirakata Y., et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002;50(Suppl. S1):25–37.
10. Kozlov R.S. Dynamics of Streptococcus pneumoniae resistance to antibiotics in Russia for the period 1999–2009 Clinical microbiology and antimicrobial chemotherapy. 2010; 12 (4): 329–341. (In Russ).
11. Krivopalov A.A., Artyushkin S.A., Tuzikov N.A. Treatment of rhinosinusogenic inflammatory intracranial complications in multidisciplinary hospital settings. Ros. Otorinolar. 2014; 5 (72): 29-34. (In Russ).
12. Lopatin A.S. Acute rhinosinusitis: clinical guidelines. Russian Society of Rhinologists. M. 2017. (In Russ).
13. Yakovlev S. V., et al. Strategy and tactics for the rational use of antimicrobial agents in outpatient practice. Eurasian clinical guidelines. 2016. Spravochnik Poliklinicheskogo Vracha. 2017; 1: 6-53. (In Russ).
14. Benninger M.S., Holy C.E., Trask D.K. Acute Rhinosinusitis: Prescription Patterns in a RealWorld Setting. Otolaryngol Head Neck Surg. 2016;154:957–962.
15. Antimicrobial therapy reference. Under the editorship of R.S. Kozlov, A.V. Dehnich. Issue 2. Smolensk: MAKHMAH, 2010. (In Russ).
16. Electronic access dated September 20, 2018: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=22c016c9-8749-4602-9933-ba80f52a1df8&t. (In Russ).
17. Strachunsky L.S., Kozlov S.N. Macrolides in modern clinical practice. Smolensk: Rusich. 1998. T. 304. (In Russ).
18. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 51–60.
19. Chatzimanolis E., Marsan N., Lefatzis D., et al. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J. Antimicrob Chemother. 1998;41(suppl. B):81–4.
20. Mira E., Benazzo M. A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. J Chemother. 2001 Dec;13(6):621-7.
21. Marsac J.H. An international clinical trial on the efficacy and safety of roxithromycin in 40,000 patients with acute community-acquired respiratory tract infections. Diagn Microbiol Infect Dis. 1992;15(suppl. 4):81S–84S.
22. Wallwork B. et al. A double‐blind, randomized, placebo‐controlled trial of macrolide in the treatment of chronic rhinosinusitis. The Laryngoscope. 2006;116(2):189-193.
23. Erokhin A.I., Gostev M.S. Antimicrobial drug Esparoxy and its use in dental practice. Klinicheskaya Praktika. 2010; P. 15. (In Russ).
24. Deffez J.P., Sheimberg A., Rezvani Y. Milticenter double-blind study of the efficacy and tolerance of roxithromycin versus erythromycin ethylsuccinate in acute orodental infection in adults. Diagn Microbiol. Infect. Dis. 1992;15:133S–37S.
25. Kaplan E.L., Chhatwal G.S., Rohde M. Reduced ability of penicillin to eradicate ingested group A streptococci from epithelial cells: clinical and pathogenetic implications. Clinical infectious diseases. 2006;43(11):1398-1406.
26. De Vlieger A., Druart M., Puttemans M. Roxithromycin versus doxycycline in the treatment of acute exacerbations of chronic bronchitis. Diagn Microbiol Infect Dis. 1992;15(suppl. 4):123S–127S.
27. Cooper B.C., Mullins P.R., Jones M.R., et al. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae. A meta-analysis of 12 clinical studies. Drug Invest. 1994;7:299-314.
28. Zharkova L.P. Roxithromycin in the treatment of respiratory tract infections. Pharmateca. 2013; 4. (In Russ).
29. Czeizel A.E., Rockenbauer M., Olsen J., et al. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obste. Gynecol. Scand. 2000;79:234–37.
30. Bazet M.C., Blanc F., Chumdermpadetsuk S., et al. Roxithromycin in the treatment of pediatric infections. Br J Clin Pract. 1988;42(Suppl. 55):117-8.
31. Johnson A. Antimicrobial Agents: Antibacterials and Antifungals Andre Bryskier, Ed. ASM Press, Washington, USA, 2005. ISBN 1-55581-237-6. 1456 pp. 2006
Review
For citations:
Krivopalov AA, Smirnov AР. The use of roxithromycin in the treatment of acute bacterial rhinosinusitis. Meditsinskiy sovet = Medical Council. 2018;(21):61-65. (In Russ.) https://doi.org/10.21518/2079-701X-2018-21-61-65
Views:
784
Email this article 